new glp 1 drug retatrutide Promises Big Weight Loss, but Safety Remains a Question Retatrutide Weight Loss | GLP-1,

These efforts have led to the development of various GLP-1 receptor agonists, the most recent being semaglutide and tirzepatide, approved for the treatment of type 2 diabetes in 2018 and 2022, respectively

[2] Other GLP-1s have similar profiles

Its not clear what percentage of patients get their weight loss drugs or any medication through telehealth, but the platforms can be vital for people who live too far away from a doctor

Standalone berberine also works through a single pathway

Additionally, it extends the C-terminal with a sequence of exenatide, and thirdly, it has an attached fatty acid side chain, similar to semaglutide, to prolong its half-life [16]

The program is billed as a monthly subscription with payments charged automatically at the billing cycle